Amunix Announces Update to Licensing Agreement With Janssen for Its Proprietary XTEN Technology
Picture Gallery, Venture Capital Wednesday, August 14th, 2013
MOUNTAIN VIEW, CA — (Marketwired) — 08/14/13 — Amunix Operating Inc. (Amunix), today announced that an option for an additional product has been exercised under its worldwide research collaboration and licensing agreement with Janssen Biotech, Inc. (Janssen). Under the exercised option, Amunix will combine its XTEN half-life extension technology with a lead therapeutic molecule selected by Janssen, which will be responsible for all preclinical and clinical development as well as the commerci
